Halozyme Therapeutics, Inc. (HALO) Receives $16.29 Average Target Price from Brokerages

Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) have been given an average rating of “Hold” by the ten brokerages that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $16.29.

HALO has been the topic of several analyst reports. ValuEngine upgraded Halozyme Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. BidaskClub upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, June 16th. Barclays PLC reiterated an “overweight” rating and set a $16.00 price target on shares of Halozyme Therapeutics in a report on Friday, June 23rd. Canaccord Genuity set a $16.00 price target on Halozyme Therapeutics and gave the company a “buy” rating in a report on Wednesday, July 26th. Finally, Jefferies Group LLC reiterated an “underperform” rating and set a $7.00 price target (up previously from $6.75) on shares of Halozyme Therapeutics in a report on Thursday, August 10th.

COPYRIGHT VIOLATION WARNING: This story was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this story on another site, it was illegally copied and reposted in violation of United States and international trademark & copyright legislation. The original version of this story can be accessed at https://sportsperspectives.com/2017/09/21/halozyme-therapeutics-inc-halo-receives-16-29-average-target-price-from-brokerages.html.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.02. The company had revenue of $33.80 million for the quarter, compared to analyst estimates of $31.76 million. During the same quarter last year, the business earned ($0.21) EPS. The company’s revenue for the quarter was up 1.2% on a year-over-year basis.

Several institutional investors and hedge funds have recently bought and sold shares of the company. BlackRock Inc. lifted its position in Halozyme Therapeutics by 4.8% in the second quarter. BlackRock Inc. now owns 11,595,500 shares of the biopharmaceutical company’s stock worth $148,652,000 after purchasing an additional 532,658 shares during the period. Iridian Asset Management LLC CT lifted its position in Halozyme Therapeutics by 2.0% in the second quarter. Iridian Asset Management LLC CT now owns 10,608,993 shares of the biopharmaceutical company’s stock worth $136,007,000 after purchasing an additional 208,605 shares during the period. Vanguard Group Inc. lifted its position in Halozyme Therapeutics by 9.5% in the second quarter. Vanguard Group Inc. now owns 9,595,212 shares of the biopharmaceutical company’s stock worth $123,010,000 after purchasing an additional 831,654 shares during the period. BB Biotech AG lifted its position in Halozyme Therapeutics by 6.7% in the second quarter. BB Biotech AG now owns 8,265,304 shares of the biopharmaceutical company’s stock worth $105,961,000 after purchasing an additional 515,472 shares during the period. Finally, Senzar Asset Management LLC lifted its position in Halozyme Therapeutics by 17.1% in the second quarter. Senzar Asset Management LLC now owns 4,087,264 shares of the biopharmaceutical company’s stock worth $52,399,000 after purchasing an additional 597,400 shares during the period. 85.06% of the stock is owned by institutional investors.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.

Analyst Recommendations for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply